MYmAb Biologics Featured on CBS News: Bringing Equity to Global Cancer Innovation

We are proud to share that MYmAb Biologics and our Founder & Director, Dr. Chua Jia Xin, were recently featured on CBS News in a special story highlighting how innovation from Southeast Asia is reshaping the future of cancer research and care. 

Equity in Cancer Research: From Personal Mission to Regional Impact

Southeast Asia faces a unique challenge in cancer care: the region reports 1.15 million new cases and 716,000 deaths annually, yet remains deeply underrepresented in global cancer research. Fewer than 10% of clinical trials include Southeast Asian populations, leaving critical knowledge gaps that affect treatment outcomes and access to cutting-edge therapies.

For Dr. Chua, this imbalance became deeply personal. After more than a decade advancing cancer immunotherapy research in the UK, she returned to Malaysia following her sibling’s battle with cancer. That experience transformed into a mission: to make science work for Southeast Asia.

Building Platforms That Change the Landscape

At MYmAb Biologics, we are building world-class scientific tools with equity at the core:

  • ArrayZeal™: A curated tissue microarray (TMA) platform with up to 150 Southeast Asian tumor specimens. This allows researchers worldwide to study cancer biology in populations that have historically been overlooked—accelerating discovery and making biomedical data more inclusive.

  • GlykoGuard™: A novel antibody development platform targeting cancer-associated glycans, abnormal sugar patterns often found in aggressive or late-stage cancers. By developing monoclonal antibodies against these signatures, MYmAb is opening pathways for precision therapies that can one day become both globally competitive and locally accessible.

Innovation from Southeast Asia, For the World

Our vision is clear: scientific excellence does not need to be imported. With the support of Malaysian agencies such as the Malaysian Bioeconomy Development Corporation and Malaysian Industrial Development Finance, MYmAb is scaling our platforms, building global collaborations, and working to ensure cancer innovation is truly inclusive.

As Dr. Chua said in the CBS feature:

“If we can develop even one more treatment option or give one more patient hope, then we’re doing what we set out to do.”
Assoc. Prof Chua Jia Xin
Founder of MYmAb Biologics

Acknowledgement

We extend our heartfelt thanks to CBS News for recognizing the importance of cancer innovation from Southeast Asia, and to Acumen Media for amplifying our story. Their coverage helps spotlight the urgent need for more inclusive science and the possibilities being built right here at home.

For the full post, read here.

At MYmAb, we believe that where you live should not determine whether you live. This recognition is another step in our journey toward making that belief a reality.